The American Journal of Managed Care2d
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...
Urine test offers simpler diagnosis for mitochondrial disorders, study finds
New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...
Guillain-Barre Syndrome: Know About The Symptoms And The Urgent Need For Early Diagnosis
Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...
'I woke up with a droopy eyelid - then rare diagnosis changed my family's life'
Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...
The American Journal of Managed Care7d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Neurological conditions that mimic Guillain-Barré Syndrome and how to differentiate them
GBS, a neurological condition triggered by an overactive immune system often after viral or bacterial infections, has been ...
PharmiWeb14d
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
Frontiers15d
Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review
The Myasthenia Gravis Foundation of America Quantitative Myasthenia Gravis ... This ocular manifestation led to a diagnosis of ocular MG, for which she commenced treatment with pyridostigmine, dosed ...
조선일보25d
KFDA approves Argenx's Vibgart for severe myasthenia gravis treatment
As symptoms worsen, they often spread throughout ... thereby providing therapeutic effects for patients with severe myasthenia gravis mediated by autoantibodies. It received approval from the ...